Compile Data Set for Download or QSAR
Report error Found 120 Enz. Inhib. hit(s) with all data for entry = 1683
TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335695(US9737544, Compound 13)
Affinity DataIC50: 15.8nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335677(US9737544, Compound 6)
Affinity DataIC50: 31.6nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335695(US9737544, Compound 13)
Affinity DataIC50: 50.1nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335681(US9737544, Compound 10)
Affinity DataIC50: 63.1nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335682(US9737544, Compound 14)
Affinity DataIC50: 63.1nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335680(US9737544, Compound 9)
Affinity DataIC50: 79.4nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335695(US9737544, Compound 13)
Affinity DataIC50: 79.4nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335677(US9737544, Compound 6)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335680(US9737544, Compound 9)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335686(US9737544, Compound 18)
Affinity DataIC50: 100nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335677(US9737544, Compound 6)
Affinity DataIC50: 126nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335681(US9737544, Compound 10)
Affinity DataIC50: 126nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335679(US9737544, Compound 8)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335679(US9737544, Compound 8)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335680(US9737544, Compound 9)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335681(US9737544, Compound 10)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335682(US9737544, Compound 14)
Affinity DataIC50: 158nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335686(US9737544, Compound 18)
Affinity DataIC50: 200nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335696(US9737544, Compound 11)
Affinity DataIC50: 200nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335673(US9737544, Compound 2)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335677(US9737544, Compound 6)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335678(US9737544, Compound 7)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335686(US9737544, Compound 18)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335695(US9737544, Compound 13)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335696(US9737544, Compound 11)
Affinity DataIC50: 251nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335678(US9737544, Compound 7)
Affinity DataIC50: 316nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335682(US9737544, Compound 14)
Affinity DataIC50: 398nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335673(US9737544, Compound 2)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335675(US9737544, Compound 4)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335675(US9737544, Compound 4)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335677(US9737544, Compound 6)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335678(US9737544, Compound 7)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335679(US9737544, Compound 8)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335680(US9737544, Compound 9)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335684(US9737544, Compound 16)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335697(US9737544, Compound 15)
Affinity DataIC50: 501nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335681(US9737544, Compound 10)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335682(US9737544, Compound 14)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335695(US9737544, Compound 13)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335696(US9737544, Compound 11)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335697(US9737544, Compound 15)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335697(US9737544, Compound 15)
Affinity DataIC50: 631nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335673(US9737544, Compound 2)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335675(US9737544, Compound 4)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335685(US9737544, Compound 17)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335685(US9737544, Compound 17)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335686(US9737544, Compound 18)
Affinity DataIC50: 794nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335672(US9737544, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trit...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335672(US9737544, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM335672(US9737544, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) was incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Trito...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 120 total ) | Next | Last >>
Jump to: